This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Raymond S. Koff, MD
Metrowest Medical Center Framingham, Mass

JAMA. 1994;272(3):201.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Drs Margolis and Presson¹ have provided a well-reasoned Editorial on host factors relevant to the suboptimal response to recombinant hepatitis B vaccines (HBVs) observed among adults and reported in that issue of JAMA.^2,3 They point out that observed differences in response to the two commercially available recombinant HBVs (Engerix-B, SmithKline Beecham Pharmaceuticals, Philadelphia, Pa, and Recombivax HB, Merck Sharp & Dohme, West Point, Pa) identified in one of the studies³ must be viewed cautiously since the design of that study was retrospective. They also indicate that prospective studies are needed to answer the question of whether or not true differences in the immunogenicity of the two vaccines exist.

A prospective, double-blind, randomized controlled trial comparing the two vaccines (20 µg of Engerix-B and 10 µg of Recombivax HB) in adults between 39 and 70 years of age (mean age, 49 years) has now been . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?